Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Bibliographic Details
Title:	Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Authors:	Schjesvold, Fredrik, Dimopoulos, Meletios A., Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Legiec, Wojciech Maciej, Pour, Ludek, Spicka, Ivan, Masszi, Tamas, Doronin, Vadim Anatolievich, Minarik, Jiri, Salogub, Galina, Alexeeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gabor, Norin, Stefan, Thuresson, Marcus, Bergan, Anna, Obermüller, Jakob, Hajek, Roman, Mateos, Maria-Victoria, Richardson, Paul G., Sonneveld, Pieter
Source:	In Blood 2 November 2023 142 Supplement 1:2018-2018
Database:	ScienceDirect